Literature DB >> 23728144

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.

Andrew J Fine1, Alfred Sorbello, Cindy Kortepeter, Linda Scarazzini.   

Abstract

We report on 20 natalizumab-treated patients with multiple sclerosis who developed laboratory-confirmed central nervous system (CNS) herpesvirus infections. In addition to progressive multifocal leukoencephalopathy, other CNS opportunistic infections have been rarely reported during natalizumab treatment. We encourage heightened awareness due to the risk for serious outcomes.

Entities:  

Keywords:  HSV; VZV; encephalitis; meningitis; natalizumab

Mesh：

Substances：

Year:  2013        PMID： 23728144     DOI： 10.1093/cid/cit376

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  43 in total

1.  Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!

Authors:  Zubeda Sheikh; Shashank Jain; Machteld Hillen
Journal:  Neurology       Date:  2016-01-29       Impact factor: 9.910

2.  Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.

Authors:  Robert W Foley; Nathan T Tagg; Matthew K Schindler; Kaylan M Fenton; Daniel S Reich; Irene Cortese; Ellen M Mowry
Journal:  Mult Scler       Date:  2017-06-22       Impact factor: 6.312

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 4.  Unintended Immunological Consequences of Biologic Therapy.

Authors:  Sarah E Henrickson; Melanie A Ruffner; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 5.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

Review 6.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 7.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

8.  Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes.

Authors:  Quanhathai Kaewpoowat; Lucrecia Salazar; Elizabeth Aguilera; Susan H Wootton; Rodrigo Hasbun
Journal:  Infection       Date:  2015-12-17       Impact factor: 3.553

Review 9.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 10.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.